Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 477-482

  Ulukaya, Engin ^a   Sarimahmut, Mehmet ^a   Cevatemre, Buse ^a   Ari, Ferda ^a   Yerlikaya, Azmi ^b   Dimas, Konstantinos ^c  

^a ULUDAG UNIVERSITY   (Turkey)

^b DUMLUPINAR UNIVERSITY   (Turkey)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Breast cancer; Chemotherapy; Cytotoxicity; Fenretinide; TRAIL

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; FENRETINIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CELL DEATH; CELL STRUCTURE; CELL VIABILITY ASSAY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; WESTERN BLOTTING; BREAST NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FENRETINIDE; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; POLY(ADP-RIBOSE) POLYMERASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84901590452     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.013     Document Type: Article

References (36)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Ulukaya E., Wood E.J. Fenretinide and its relation to cancer. Cancer Treat Rev 1999, 25:229-235.
3. Cazzaniga M., Varricchio C., Montefrancesco C., Feroce I., Guerrieri-Gonzaga A. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?. J Biomed Biotechnol 2012, 2012:172897.
4. Ulukaya E., Pirianov G., Kurt M.A., Wood E.J., Mehmet H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarization. Cell Death Differ 2003, 10:856-859.
5. Simeone A.M., Ekmekcioglu S., Broemeling L.D., Grimm E.A., Tari A.M. A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther 2002, 1:1009-1017.
6. Ohlmann C.H., Jung C., Jaques G. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?. Int J Cancer 2002, 100:520-526.
7. Appierto V., Tiberio P., Villani M.G., Cavadini E., Formelli F. PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation. Carcinogenesis 2009, 30:824-831.
8. Messner M.C., Cabot M.C. Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells. Cancer Chemother Pharmacol 2011, 68:477-487.
9. Li X., Ling W., Pennisi A., Khan S., Yaccoby S. Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett 2009, 284:175-181.
10. Reynolds C.P., Matthay K.K., Villablanca J.G., Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003, 197:185-192.
11. Decensi A., Bonanni B., Guerrieri-Gonzaga A., Torrisi R., Manetti L., Robertson C., et al. Chemoprevention of breast cancer: the Italian experience. J Cell Biochem Suppl 2000, 34:84-96.
12. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R., et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006, 17:1065-1071.
13. Hail N., Kim H.J., Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694.
14. Xie H., Zhu F., Huang Z., Lee M.H., Kim D.J., Li X., et al. Identification of mammalian target of rapamycin as a direct target of fenretinide both in vitro and in vivo. Carcinogenesis 2012, 33:1814-1821.
15. Rahmaniyan M., Curley R.W., Obeid L.M., Hannun Y.A., Kraveka J.M. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J Biol Chem 2011, 286:24754-24764.
16. Almasan A., Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14:337-348.
17. Formelli F., Cleris L. Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur J Cancer 2000, 36:2411-2419.
18. Kocdor H., Kocdor M.A., Canda T., Gurel D., Cehreli R., Yilmaz O., et al. Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis. Clin Transl Oncol 2009, 11:243-249.
19. Lovat P.E., Ranalli M., Bernassola F., Tilby M., Malcolm A.J., Pearson A.D.J., et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer 2000, 88:977-985.
20. Kouhara J., Yoshida T., Nakata S., Horinaka M., Wakada M., Ueda Y., et al. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol 2007, 30:679-687.
21. Cuello M., Coats A.O., Darko I., Ettenberg S.A., Gardner G.J., Nau M.M., et al. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004, 11:527-541.
22. Papagiannaros A., Hatziantoniou S., Konstantinos D., Papaioannou G.T., Demetzos C. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Biomed Pharmacother 2005, 60:36-42.
23. Andreotti P.E., Cree I.A., Kurbacher C.M. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995, 55:5276-5282.
24. Ulukaya E., Ozdikicioglu F., Oral A.Y., Demirci M. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicol In Vitro 2008, 22:232-239.
25. Ulukaya E., Acilan C., Yilmaz Y. Apoptosis: why and how does it occur in biology?. Cell Biochem Funct 2011, 29:468-480.
26. Biosoft CalcuSyn for Windows, Software for Dose Effect Analysis 1996, 9-18. Biosoft, Cambridge.
27. Sabichi A.L., Lerner S.P., Atkinson E.N., Grossman H.B., Caraway N.P., Dinney C.P., et al. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 2008, 14:224-229.
28. Rehman F., Shanmugasundaram P., Schrey M.P. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Br J Cancer 2004, 91:1821-1828.
29. Shao R., Lee D.F., Wen Y., Ding Y., Xia W., Ping B., et al. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Mol Cancer Res 2005, 3:219-226.
30. Kisim A., Atmaca H., Cakar B., Karabulut B., Sezgin C., Uzunoglu S., et al. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res ClinOncol 2012, 138:1155-1163.
31. Lee J., Hwangbo C., Lee J.J., Seo J., Lee J.H. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Oncol Rep 2010, 23:229-237.
32. Ulukaya E., Colakogullari M., Wood E.J. Interference by anti-cancer chemotherapeutic agents in the MTT - tumor chemosensitivity assay. Chemotherapy 2004, 50:43-50.
33. Singh K., Mogare D., Giridharagopalan R.O., Gogiraju R., Pande G., Chattopadhyay S. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell migration and invasion. PLoS One 2007, 2:e660.
34. Lacroix M., Toillon R.A., Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer 2006, 13:293-325.
35. Hui L., Zheng Y., Yan Y., Bargonetti J., Foster D.A. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006, 25:7305-7310.
36. White D.E., Burchill S.A. Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours. Br J Cancer 2010, 103:1380-1390.